|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
DE3169595D1
(en)
|
1980-11-10 |
1985-05-02 |
Gersonde Klaus |
Method of preparing lipid vesicles by ultrasonic treatment, the use of this method and apparatus for its application
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
EP0088046B1
(de)
|
1982-02-17 |
1987-12-09 |
Ciba-Geigy Ag |
Lipide in wässriger Phase
|
|
DE3218121A1
(de)
|
1982-05-14 |
1983-11-17 |
Leskovar, Peter, Dr.-Ing., 8000 München |
Arzneimittel zur tumorbehandlung
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
EP0143949B1
(en)
|
1983-11-01 |
1988-10-12 |
TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION |
Pharmaceutical composition containing urokinase
|
|
JPS62126123A
(ja)
|
1985-11-28 |
1987-06-08 |
Shigeki Suzuki |
バルプロ酸の経皮吸収方法
|
|
CA2115840A1
(en)
|
1991-08-27 |
1993-03-04 |
Tsung-Min Hsu |
Transdermal formulation for administering prazosin
|
|
EP0819016A1
(de)
|
1995-04-07 |
1998-01-21 |
Novartis AG |
Iontophoretisches transdermales system zum verabreichen von mindestens zwei substanzen
|
|
US5736154A
(en)
|
1996-03-11 |
1998-04-07 |
Fuisz Technologies Ltd. |
Transdermal delivery system
|
|
FR2749514B1
(fr)
|
1996-06-11 |
1998-08-07 |
Hoechst Marion Roussel |
Systemes transdermiques renfermant 2 principes actifs dans des compartiments separes, leur procede de preparation et leur application comme medicament
|
|
US6479074B2
(en)
|
1996-10-24 |
2002-11-12 |
Pharmaceutical Applications Associates Llc |
Methods and transdermal compositions for pain relief
|
|
AU5495798A
(en)
*
|
1997-01-16 |
1998-08-07 |
Sekisui Chemical Co., Ltd. |
External preparations for percutaneous absorption
|
|
CA2335837A1
(en)
|
1998-06-29 |
2000-01-06 |
Pharmaceuticals Applications Associates, Llc |
Methods and transdermal compositions for pain relief
|
|
CA2377385A1
(en)
|
1999-06-03 |
2000-12-14 |
Jessie L.S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
IL138686A0
(en)
|
1999-10-01 |
2001-10-31 |
Pfizer Prod Inc |
α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
|
|
ES2273873T3
(es)
|
2000-07-14 |
2007-05-16 |
Transform Pharmaceuticals, Inc. |
Sistema y procedimiento para la optimizacion de la transferencia de compuestos a traves de una barrera de tejido.
|
|
US6682757B1
(en)
*
|
2000-11-16 |
2004-01-27 |
Euro-Celtique, S.A. |
Titratable dosage transdermal delivery system
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
EP1293205A1
(en)
|
2001-09-18 |
2003-03-19 |
G2M Cancer Drugs AG |
Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
|
|
WO2003049774A1
(en)
|
2001-12-13 |
2003-06-19 |
Vital Health Sciences Pty Ltd |
Transdermal transport of compounds
|
|
US6841565B1
(en)
|
2002-03-29 |
2005-01-11 |
The Ohio State University |
Treatment of patients with chronic lymphocytic leukemia
|
|
AR044399A1
(es)
|
2003-05-20 |
2005-09-14 |
Novartis Ag |
Compuestos heterociclicos y su uso como activadores de receptores de ppar. composiciones farmaceuticas que los contienen
|
|
CA2531418A1
(en)
|
2003-07-08 |
2005-01-20 |
Novartis Ag |
Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
US8012944B2
(en)
|
2003-10-30 |
2011-09-06 |
Pharmascience Inc. |
Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
|
|
CA2600973C
(en)
|
2003-11-26 |
2012-08-07 |
Novartis Ag |
.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid
|
|
WO2005065668A2
(en)
|
2003-12-29 |
2005-07-21 |
Qlt Usa, Inc. |
Topical compositions comprising halo-deoxyadenosines for treatment of skin disorders
|
|
US20050255150A1
(en)
|
2004-04-26 |
2005-11-17 |
Cassel Douglas R |
Wound treatment patch for alleviating pain
|
|
KR100602434B1
(ko)
|
2004-09-10 |
2006-07-19 |
최상식 |
복수 개의 단위 구획을 포함하는 약물의 경피 투여용 패치
|
|
AU2006283677A1
(en)
|
2005-08-19 |
2007-03-01 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Topical formulations of histone deacetylase inhibitors and methods of using the same
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
WO2007041584A2
(en)
|
2005-10-03 |
2007-04-12 |
Combinatorx, Incorporated |
Implantable sensors, implantable pumps, and anti-scarring drug combinations
|
|
CA2630334C
(en)
|
2005-11-16 |
2013-07-23 |
Universidad Nacional Autonoma De Mexico |
Use of transcriptome-modifying agents and chemotherapy or radiotherapy against cancer
|
|
US20090324587A1
(en)
|
2005-12-01 |
2009-12-31 |
Neal Clifford Goodwin |
Cancer Therapies and Pharmaceutical Compositions Used Therein
|
|
EP1963532A4
(en)
|
2005-12-07 |
2010-07-21 |
Univ Utah Res Found |
DNA METHYLATION AS A TARGET FOR DIAGNOSIS AND TREATMENT OF CHRONIC LYMPHOCYTE LEUKEMIA (CLL)
|
|
EP1993553B1
(en)
|
2006-03-02 |
2013-05-08 |
Agency for Science, Technology and Research |
Methods for cancer therapy and stem cell modulation
|
|
US8585753B2
(en)
|
2006-03-04 |
2013-11-19 |
John James Scanlon |
Fibrillated biodegradable prosthesis
|
|
US8338416B2
(en)
*
|
2006-03-16 |
2012-12-25 |
Pharmacylics, Inc. |
Indole derivatives as inhibitors of histone deacetylase
|
|
EP2389930A1
(en)
|
2006-03-31 |
2011-11-30 |
Erasmus University Medical Center Rotterdam |
Novel composition for tumor growth control
|
|
JP2009536228A
(ja)
*
|
2006-05-05 |
2009-10-08 |
コロプラスト アクティーゼルスカブ |
架橋ポリアルキレンオキシド及び親水性吸水剤を含む感圧接着剤組成物
|
|
US20110104177A1
(en)
|
2006-12-28 |
2011-05-05 |
The Johns Hopkins University |
Histone deacetylase inhibitors, combination therapies and methods of use
|
|
CA2677651A1
(en)
|
2007-02-15 |
2008-08-21 |
Novartis Ag |
Combinations of therapeutic agents for treating cancer
|
|
WO2008116163A1
(en)
|
2007-03-22 |
2008-09-25 |
Oregon Health & Science University |
Therapeutic drug combinations for treatment of b-cell malignancies
|
|
WO2008127735A1
(en)
|
2007-04-13 |
2008-10-23 |
Stemline Therapeutics, Inc. |
Il3ralpha antibody conjugates and uses thereof
|
|
US20090025274A1
(en)
|
2007-07-23 |
2009-01-29 |
Tim Lail |
Animal trap
|
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
|
WO2009067453A1
(en)
*
|
2007-11-19 |
2009-05-28 |
Syndax Pharmaceuticals, Inc. |
Combinations of hdac inhibitors and proteasome inhibitors
|
|
WO2009067543A2
(en)
|
2007-11-19 |
2009-05-28 |
The Regents Of The University Of Colorado |
Treatment of histone deacetylase mediated disorders
|
|
DK3782612T3
(da)
|
2008-05-15 |
2024-01-15 |
Celgene Corp |
Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
|
|
WO2009155477A1
(en)
|
2008-06-19 |
2009-12-23 |
The Trustees Of The University Of Pennsylvania |
Inducible regulatory t-cell generation for hematopoietic transplants
|
|
WO2010020787A1
(en)
|
2008-08-22 |
2010-02-25 |
Oncomethylome Sciences Sa |
Diagnosis and treatment of tumours
|
|
RU2636614C2
(ru)
*
|
2009-05-19 |
2017-11-24 |
Вивия Байотек С.Л. |
Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
|
|
US8491927B2
(en)
*
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
|
JP5548470B2
(ja)
*
|
2010-02-16 |
2014-07-16 |
日本碍子株式会社 |
ハニカム触媒体
|
|
US20110245154A1
(en)
*
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
|
EP2382993A1
(en)
*
|
2010-04-19 |
2011-11-02 |
KTB Tumorforschungsgesellschaft mbH |
Combination of drugs with protein-binding prodrugs
|
|
WO2012044936A1
(en)
*
|
2010-09-30 |
2012-04-05 |
Portola Pharmaceuticals, Inc. |
Combination therapy with 4-(3-(2h-1,2,3-triazol-2-yl)phenylamino)-2-((1r,2s)-2-aminocyclohexylamino)pyrimidine-5-carboxamide
|
|
EP2786755A3
(en)
*
|
2010-11-12 |
2014-10-29 |
Pharma Mar S.A. |
Combination therapy with an antitumor alkaloid
|
|
US20130004481A1
(en)
*
|
2011-01-12 |
2013-01-03 |
Boehringer Ingelheim International Gmbh |
Anticancer therapy
|
|
BR112013025798A2
(pt)
*
|
2011-04-08 |
2016-12-20 |
Afraxis Holdings Inc |
8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para o tratamento de câncer e distúrbios de sistema nervoso
|
|
WO2012142480A1
(en)
*
|
2011-04-14 |
2012-10-18 |
Beth Israel Deaconess Medical Center, Inc. |
Chimeric rna oligonucleotides and uses thereof
|
|
US20140170148A1
(en)
*
|
2011-04-20 |
2014-06-19 |
Genmab A/S |
Bispecific antibodies against her2
|
|
JP2014519813A
(ja)
*
|
2011-04-25 |
2014-08-21 |
オーエスアイ・ファーマシューティカルズ，エルエルシー |
癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
|
|
WO2013003629A2
(en)
*
|
2011-06-28 |
2013-01-03 |
Pharmacyclics, Inc. |
Methods and compositions for inhibition of bone resorption
|
|
JP6162709B2
(ja)
*
|
2011-11-01 |
2017-07-12 |
セルジーン コーポレイション |
シチジンアナログの経口製剤を使用して癌を治療する方法
|
|
WO2013086451A2
(en)
*
|
2011-12-09 |
2013-06-13 |
Afraxis, Inc. |
Pak inhibitors for the treatment of cancer
|
|
WO2013181462A1
(en)
*
|
2012-05-31 |
2013-12-05 |
Amgen Inc. |
Use of amg 900 for the treatment of cancer
|
|
MA37711A1
(fr)
*
|
2012-06-04 |
2017-05-31 |
Pharmacyclics Inc |
Formes cristallines d'un inhibiteur de tyrosine kinase de bruton
|
|
WO2014009318A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
|
|
WO2014009319A1
(en)
*
|
2012-07-11 |
2014-01-16 |
Boehringer Ingelheim International Gmbh |
Indolinone derivatives anticancer compounds
|
|
UA116544C2
(uk)
*
|
2012-08-09 |
2018-04-10 |
Селджин Корпорейшн |
Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
LT2882737T
(lt)
*
|
2012-08-09 |
2019-04-25 |
Celgene Corporation |
(s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
|
|
AU2013302696B9
(en)
*
|
2012-08-14 |
2018-08-09 |
Ibc Pharmaceuticals, Inc. |
T-cell redirecting bispecific antibodies for treatment of disease
|
|
US9682143B2
(en)
*
|
2012-08-14 |
2017-06-20 |
Ibc Pharmaceuticals, Inc. |
Combination therapy for inducing immune response to disease
|
|
US20140120083A1
(en)
*
|
2012-11-01 |
2014-05-01 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
|
CN107753954A
(zh)
*
|
2012-12-13 |
2018-03-06 |
免疫医疗公司 |
功效改进且毒性降低的抗体与sn‑38的免疫缀合物的剂量
|